Hengrui Pharma Subsidiaries Receive Two Clinical Trial Approvals from China NMPA
Hengrui Pharma (600276) announced on September 15, 2026, that its subsidiary Fujian Shengdi Pharmaceutical Co. , Ltd. received a Drug Clinical Trial Approval Notice approved and issued by the National Medical Products Administration for HRS-4139 tablets.
A separate announcement the same day showed that another subsidiary, Guangdong Hengrui Pharmaceutical Co. , received a Drug Clinical Trial Approval Notice approved and issued by the National Medical Products Administration for injectable recaticimab. Both notices were approved and issued by the National Medical Products Administration.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 40/100 and 70% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.